## THE ANATOLIAN JOURNAL OF CARDIOLOGY

## Rare Hypersensitivity Myocardial Reactions Following COVID-19 Vaccination: Hypersensitivity Myocardial Infarction (Kounis Syndrome) and Hypersensitivity Myocarditis

Previous epidemiological data have demonstrated that approximately 85% of vaccine anaphylaxis cases had a history of prior allergic disease and that women are at a greater risk than men.<sup>1-3</sup> In this concept, the published report in *Anatolian Journal of Cardiology*<sup>4</sup> concerning a 22-year-old woman with previous egg and tomato allergy and drug allergies to unknown medicines who developed acute myocardial infarction (AMI) of the Kounis type following the first dose of COVID-19 vaccine (BNT162b2, Pfizer-BioNTech) is very important. It raises important issues on Kounis hypersensitivity AMI, hypersensitivity myocarditis, and future measures in order to avoid and prevent these rare COVID-19 vaccine hypersensitivities.

Indeed, in only 9, so far, worldwide reports of AMI following COVID-19 vaccines, the authors have speculated on Kounis hypersensitivity-associated AMI despite the absence of atopic background. Specifically, Kounis syndrome-like AMI has occurred in 2 patients after the Moderna vaccine,<sup>5,6</sup> in an 86-year-old<sup>7</sup> and in a healthy 96-year-old<sup>8</sup> female following the first dose of Pfizer–BioNTech and Moderna vaccine, respectively, in a 62-year-old woman<sup>9</sup> after the first dose of AstraZeneca, in a 41-year-old woman<sup>10</sup> after the first dose of inactivated coronavirus vaccine (Sinovac Life Sciences, Beijing, China), in a healthy 63-year-old<sup>11</sup> and two, 46- and 48-year-old males<sup>12</sup> after the Covishield vaccine, respectively (similar to AstraZeneca that is manufactured in India). All of the above vaccines contain excipients such as polysorbate 80 (AstraZeneca and Covishield), polyethylene glycol, also known as macrogol or PEG (Pfizer-BioNTech and Moderna), and tromethamine, also known as trometamol (Moderna) that could potentially induce hypersensitivity reactions.

Myocarditis after the first dose of Pfizer–BioNTech vaccine has been reported in a 21-year-old man with a previous history of atopic asthma in childhood and pollen and pet allergy.<sup>13</sup> Moreover, in 1 fatal case from Korea,<sup>14</sup> in 2 patients from the United States,<sup>15</sup> and in 1 patient from Israel,<sup>16</sup> who demonstrated mRNA COVID-19 vaccination-induced-myocarditis, a myocardial biopsy revealed myocardial infiltration by eosinophils and other inflammatory cells. All of the above support the view that COVID-19 vaccine-associated myocarditis seems similar to hypersensitivity myocarditis<sup>17</sup> which is a subtype of eosinophilic myocarditis. Of these patients, 36.5% may have not peripheral eosinophilia and most patients respond well to drug removal or steroid administration.<sup>18</sup>

Creams, ointments, lotions, cosmetics, and dental materials also contain polysorbate and polyethylene glycol (PEG), as excipients, that are able to sensitize their users. It has been reported that 1-5.4% of the general population has been sensitized to cosmetics or dental materials.<sup>19</sup> Therefore, hypersensitivity-induced Kounis syndrome and hypersensitivity myocarditis could be induced by the above materials. This fact has forced researchers to suggest alternative and different<sup>20</sup> excipients in vaccine manufacturing if vaccine component-induced hypersensitivity is confirmed by further systematic future investigations.<sup>1</sup> Searching for agents that are able to reduce immunogenicity, improve stability, suppress oxidative damage, and prevent thrombotic and cardiovascular events is very important.

Content of this journal is licensed under a Creative Commons Attribution-NonCommercial

Copyright@Author(s) - Available online at anatoljcardiol.com.

4.0 International License



## LETTER TO THE EDITOR

Nicholas G. Kounis<sup>10</sup> Ioanna Koniari<sup>10</sup> Virginia Mplani<sup>10</sup> Sophia Kouni<sup>10</sup> Dimitrios Velissaris<sup>10</sup> Panagiotis Plotas<sup>10</sup> Grigorios Tsigkas<sup>10</sup>

<sup>1</sup>Department of Cardiology, University of Patras Medical School, Patras, Greece <sup>2</sup>Department of Cardiology, University Hospital of South Manchester NHS Foundation Trust, Manchester, UK <sup>3</sup>Intensive Care Unit, University of Patras Medical School, Patras, Greece <sup>4</sup>Department of Internal Medicine, University of Patras Medical School, Patras, Greece

Corresponding author: Nicholas G. Kounis Makounis@otenet.gr

**Cite this article as:** Kounis NG, Koniari I, Mplani V, et al. Rare hypersensitivity myocardial reactions following COVID-19 vaccination: hypersensitivity myocardial infarction (Kounis syndrome) and hypersensitivity myocarditis. Anatol J Cardiol 2022;26(3):245-246.

DOI:10.5152/AnatolJCardiol.2022.1573

COVID-19-free allergenic vaccines might prove more suitable and more beneficial without inducing these, indeed very rare, hypersensitivity Kounis syndrome and hypersensitivity myocarditis.

## REFERENCES

- Warren CM, Snow TT, Lee AS, et al. Assessment of allergic and anaphylactic reactions to mRNA COVID-19 vaccines with confirmatory testing in a US Regional Health System. JAMA Netw Open. 2021;4(9):e2125524. [CrossRef]
- Clark S, Wei W, Rudders SA, Camargo CA Jr. Risk factors for severe anaphylaxis in patients receiving anaphylaxis treatment in US emergency departments and hospitals. J Allergy Clin Immunol. 2014;134(5):1125-1130. [CrossRef]
- McNeil MM, Weintraub ES, Duffy J, et al. Risk of anaphylaxis after vaccination in children and adults. *J Allergy Clin Immunol*. 2016;137(3):868-878. [CrossRef]
- Şancı E, Örçen C, Çelik OM, Özen MT, Bozyel S. Kounis syndrome associated with BNT162b2 mRNA COVID-19 vaccine presenting as ST-elevation acute myocardial infarction. *Anatol J Cardiol.* 2022;26(1):72-74. [CrossRef]
- Sung JG, Sobieszczyk PS, Bhatt DL. Acute myocardial infarction Within 24 hours after COVID-19 vaccination. Am J Cardiol. 2021;156:129-131. [CrossRef]
- Kounis NG, Koniari I, Mplani V, Kouni SN, Plotas P, Tsigkas G. Acute myocardial infarction within 24 hours after COVID-19 vaccination: is Kounis syndrome the culprit? *Am J Cardiol.* 2022;162:207. [CrossRef]
- Tajstra M, Jaroszewicz J, Gąsior M. Acute coronary tree thrombosis after vaccination for COVID-19. JACC Cardiovasc Interv. 2021;14(9):e103-e104. [CrossRef]
- Boivin Z, Martin J. Untimely myocardial infarction or COVID-19 vaccine side effect. *Cureus*. 2021;13(3):e13651. [CrossRef]
- Maadarani O, Bitar Z, Elzoueiry M, et al. Myocardial infarction post COVID-19 vaccine - coincidence, Kounis syndrome or other explanation - time will tell. JRSM Open. 2021;12(8): 20542704211025259. [CrossRef]

- Özdemir İH, Özlek B, Özen MB, Gündüz R, Bayturan Ö. Type 1 Kounis syndrome induced by inactivated SARS-COV-2 vaccine. *J Emerg Med*. 2021;61(4):e71-e76. [CrossRef]
- Chatterjee S, Ojha UK, Vardhan B, Tiwari A. Myocardial infarction after COVID-19 vaccination-casual or causal? *Diabetes Metab Syndr*. 2021;15(3):1055-1056. [CrossRef]
- Srinivasan I. KN, Sathyamurthy I, Neelagandan M. Relation between COVID-19 vaccination and myocardial infarction – casual or coincidental? IHJ Cardiovascular Case Reports (CVCR). 2021;5:7174.
- Sokolska JM, Kurcz J, Kosmala W. Every rose has its thorns acute myocarditis following COVID-19 vaccination. *Kardiol Pol.* 2021;79(10):1153-1154. [CrossRef]
- Choi S, Lee S, Seo JW, et al. Myocarditis-induced sudden death after BNT162b2 mRNA COVID-19 vaccination in Korea: case report focusing on histopathological findings. *J Korean Med Sci.* 2021;36(40):e286. [CrossRef]
- Verma AK, Lavine KJ, Lin CY. Myocarditis after Covid-19 mRNA vaccination. N Engl J Med. 2021;385(14):1332-1334. [CrossRef]
- Witberg G, Barda N, Hoss S, et al. Myocarditis after Covid-19 vaccination in a large health care organization. N Engl J Med. 2021;385(23):2132-2139. [CrossRef]
- 17. Kounis NG, Zavras GM, Soufras GD, Kitrou MP. Hypersensitivity myocarditis. *Ann Allergy*. 1989;62(2):71-74.
- Brambatti M, Matassini MV, Adler ED, Klingel K, Camici PG, Ammirati E. Eosinophilic myocarditis: characteristics, treatment, and outcomes. J Am Coll Cardiol. 2017;70(19):2363-2375. [CrossRef]
- Lyapina MG, Stoyanova Dencheva M. Contact sensitization to ingredients of dental materials and cosmetics in dental students: a pilot study. *Cent Eur J Public Health*. 2019;27(1):73-77. [CrossRef]
- Mortz CG, Kjaer HF, Rasmussen TH, Rasmussen HM, Garvey LH, Bindslev-Jensen C. Allergy to polyethylene glycol and polysorbates in a patient cohort: diagnostic work-up and decision points for vaccination during the COVID-19 pandemic. *Clin Transl Allergy*. 2022;12(1):e12111. [CrossRef]